Back to search

Institutional Repository of Vilnius University

Imunoepigenetinių žymenų analizė ir sąsajos su klinikiniais rodikliais šlapimo pūslės vėžiu sergančiuose pacientuose /

Abstract

dc:description

Bladder cancer ranks as the 9th most common malignancy in the world and has a notably high heterogeneity and recurrence rate after standard treatment combined with local immunother-apy, which is inefficient in approximately 40% of the patients. Bladder cancer is recognized for its ability to evade antitumor immune response, and it is believed that the analysis of genes and their proteins, involved in immune regulation, may help to understand and resolve immunosensitivity to immunotherapeutic drugs. This study is aimed at identifying significant immunoepigenetic biomarkers and their quanti-ty changes, which would allow non-invasive monitoring of disease progression. Flow cytometry was used to analyse concentration changes of the 10 most common immune checkpoints (ICs) and their ligands, including sCD25, 4-1BB, B7.2, TGF-&#946;1,CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, and Gal-9, and DNA methylation changes in CD223, LGALS9, PDCD1, FOXP3, FOXP1 in patients’ paired tumor and urine samples. The levels of sCD25, PD-L1 and Gal-9 were found to be at least 2-fold higher (p¬=0.0053, p=0.0189 and p<0.0001, respectively) vs controls (bladder cancer free patients). Also, sCD25, B7.2 and LAG-3 concentrations were up to 5-fold in pTa stage than in pT2a stage (p=0.0290, p=0.0072, p=0.0109, respectively), while B7.2 was also prominent in the group of patients with G2 differen-tiation grade, where the levels were 2 times higher than in the G1 (p=0.0179) or G3 (p=0.0385) groups. As of DNA methylation results, it showed that PDCD1 and FOXP3 methylation levels were significantly different in urine samples compared to tumour tissue (4.8-fold, p<0.0001 and 1.4-fold, p=0.0477 respectively). The clinical significance of LGALS9, PDCD1 and FOXP3 in urine samples was also revealed. In case of LGALS9, differences were found between pTa and pT1 stages (p = 0.0419), PDCD1 between pTa and pT2a (p = 0.0250) and FOXP3 - between G1-G2 and G1-G3 differentiation stage groups (p=0.0411 and p=0.020). In addition, a general trend of de-creased methylation levels was observed in immunogenically active patients. These results suggest that plasma circulating ICs sCD25, B7.2, PD-L1 and Gal-9 and the methylation level changes of LGAS9, PDCD1 and FOXP3 in urine may be useful as non-invasive tools for monitoring bladder cancer.

Degree

thesis:*
Grantor dc:publisher
Institutional Repository of Vilnius University
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Remeikaitė, Nerija,

Rights

dc:rights
Statement dc:rights
  • info:eu-repo/semantics/openAccess
Language dc:language
lit

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
Vilnius University
Base URL
epublications.vu.lt/oai
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Remeikaitė, Nerija,. Imunoepigenetinių žymenų analizė ir sąsajos su klinikiniais rodikliais šlapimo pūslės vėžiu sergančiuose pacientuose /. Institutional Repository of Vilnius University, 2025. https://repository.vu.lt/VU:ELABAETD239023903&prefLang=en_US